BTIG Reiterates Buy on Carlsmed, Maintains $23 Price Target

BTIG analyst Ryan Zimmerman has reiterated a Buy rating on Carlsmed (NASDAQ: CARL) and maintained a price target of $23 for the stock. This recommendation suggests confidence in the company's performance and potential for growth.